NCT01427023

Brief Summary

The objective of this study is to obtain female first-catch urine, vaginal swab, endocervical swab, and cervical specimens collected in PreservCyt Solution ("PreservCyt Specimens") for testing with the APTIMA Trichomonas vaginalis (ATV) Assay. These specimens will be used to demonstrate assay performance on the PANTHER System is comparable to performance on the TIGRIS System.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
532

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2012

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 26, 2011

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 1, 2011

Completed
11 months until next milestone

Study Start

First participant enrolled

August 1, 2012

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

February 6, 2014

Status Verified

February 1, 2014

Enrollment Period

7 months

First QC Date

August 26, 2011

Last Update Submit

February 5, 2014

Conditions

Keywords

APTIMA Trichomonas vaginalis AssayAPTIMAtrichomonastrichomonas vaginalis

Outcome Measures

Primary Outcomes (2)

  • Positive Percent Agreement Using the TIGRIS Instrument as a Reference.

    Positive Percent Agreement Using the TIGRIS Instrument as a Reference.

    approximately one year

  • Negative Percent Agreement Using the TIGRIS Instrument as a Reference.

    Negative Percent Agreement Using the TIGRIS Instrument as a Reference.

    approximately one year

Secondary Outcomes (1)

  • Positivity Rate

    approximately one year

Interventions

APTIMA Trichomonas vaginalis (ATV) Assay

Eligibility Criteria

Age14 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Women attending participating US OB/GYN, family planning, or STD clinics will be eligible to participate.

You may qualify if:

  • Subject must be female and attend a participating clinic
  • Subject must be at least 14 years of age at the time of enrollment and is currently sexually active (has had vaginal intercourse within the past 12 months)
  • The subject and/or legally authorized representative is willing to undergo the informed consent process prior to study participation (a minor will need the documented consent of her parent or legal guardian, unless the site has an institutional review board (IRB)- approved waiver for parental consent for minors)
  • In addition, the subject must meet at least one of the following criteria:
  • Subject must demonstrate symptoms consistent with a suspected STD such as vaginal odor, vaginal discharge, vaginal/vulvar itching or irritation, pain/discomfort during sexual intercourse or urination, and/or lower abdominal discomfort
  • Subject must be asymptomatic and known to be partners with, or a contact of, a person with a confirmed or suspected STD(s)
  • Subject must be asymptomatic and undergoing screening evaluation for possible STDs
  • Subject must be undergoing Pap screening

You may not qualify if:

  • Subject took antibiotic medications within the last 14 days
  • Subject already participated in the study
  • Subject has a history of illness that the principal investigator (PI) or designee considers could interfere with or affect the conduct, results, and/or completion of the clinical trial
  • Subject has a history of illness that the PI or designee considers could create an unacceptable risk to the subject if enrolled

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

University of Alabama, Birmingham

Birmingham, Alabama, 35294, United States

Location

Wishard Hospital - Indiana University School of Medicine

Indianapolis, Indiana, 46202, United States

Location

Louisiana State University

New Orleans, Louisiana, 70112, United States

Location

New England Center for Clinical Research

Fall River, Massachusetts, 02720, United States

Location

University of North Carolina, Chapel Hill

Chapel Hill, North Carolina, 27599, United States

Location

Geneuity Clinical Research Services

Maryville, Tennessee, 37804, United States

Location

Planned Parenthood Gulf Coast

Houston, Texas, 77023, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

urine specimen, vaginal swab specimen, endocervical swab specimen and PreservCyt specimen

MeSH Terms

Conditions

Trichomonas Infections

Interventions

Biological Assay

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfections

Intervention Hierarchy (Ancestors)

Investigative Techniques

Study Officials

  • Jennifer Reid, PhD

    Gen-Probe, Incorporated

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 26, 2011

First Posted

September 1, 2011

Study Start

August 1, 2012

Primary Completion

March 1, 2013

Study Completion

December 1, 2013

Last Updated

February 6, 2014

Record last verified: 2014-02

Locations